Filing Flows › Sanara MedTech (SMTI) › Q2 2026 › vs Q1 2026
Sanara MedTech (SMTI) Q2 2026 vs Q1 2026 (quarter over quarter)
Sanara MedTech's revenue rose $338K (+1%) from $27.8M in Q1 2026 to $28.1M in Q2 2026. The biggest changes: Soft Tissue Repair Products +$300K (+1%); Bone Fusion Products +$39K (+1%).
Sanara MedTech, Q2 2026: revenue $28.1M (+9% year over year), operating margin 6.3%, net loss $453K, operating cash flow $2.0M. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Free cash flow margin | 7.2% | -9.0% | +16.3 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Soft Tissue Repair Products | $25.2M | $24.9M | $300K | +1% |
| Bone Fusion Products | $2.9M | $2.9M | $39K | +1% |
| Revenue | $28.1M | $27.8M | $338K | +1% |
| Net loss | $453K | −$459K | $911K | — |
| Costs & expenses | $28.6M | $27.8M | $791K | +3% |
| Operating costs | $26.4M | $25.2M | $1.2M | +5% |
| Interest & other, net | $2.2M | $2.2M | $45K | +2% |
| Cost of revenue | $2.0M | $1.9M | $58K | +3% |
| Research & development | $1.2M | $760K | $395K | +52% |
| Sales & marketing | $16.9M | $17.0M | −$138K | -0.8% |
| General & admin | $5.7M | $4.9M | $858K | +18% |
| Other operating costs | $619K | $587K | $32K | +5% |
| Operating cash sources | $2.5M | −$2.9M | $5.4M | — |
| Depreciation & amortization | $619K | $587K | $32K | +5% |
| Share-based compensation | $1.5M | $1.0M | $468K | +46% |
| Working capital & other | $376K | −$4.5M | $4.9M | — |
| Net loss absorbed | $453K | −$459K | $911K | — |
| Operating cash flow | $2.0M | −$2.5M | $4.5M | — |
| Free cash flow (OCF − capex) | $2.0M | −$2.5M | $4.5M | — |
| Capital expenditures | $5K | $44K | −$38K | -88% |
Questions
How much did Sanara MedTech's revenue grow quarter over quarter in Q2 2026?
Sanara MedTech's revenue rose $338K (+1%) from $27.8M in Q1 2026 to $28.1M in Q2 2026.
What drove Sanara MedTech's revenue change in Q2 2026?
Soft Tissue Repair Products +$300K (+1%); Bone Fusion Products +$39K (+1%).